BR112022022599A2 - Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma - Google Patents

Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma

Info

Publication number
BR112022022599A2
BR112022022599A2 BR112022022599A BR112022022599A BR112022022599A2 BR 112022022599 A2 BR112022022599 A2 BR 112022022599A2 BR 112022022599 A BR112022022599 A BR 112022022599A BR 112022022599 A BR112022022599 A BR 112022022599A BR 112022022599 A2 BR112022022599 A2 BR 112022022599A2
Authority
BR
Brazil
Prior art keywords
methods
covid
analogs
treatment
bardoxolone methyl
Prior art date
Application number
BR112022022599A
Other languages
English (en)
Inventor
Ferguson Deborah
Christian Wigley W
Meyer Colin
Warren Huff J
M Kral Robert Jr
Original Assignee
Reata Pharmaceuticals Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Holdings Llc filed Critical Reata Pharmaceuticals Holdings Llc
Publication of BR112022022599A2 publication Critical patent/BR112022022599A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

MÉTODOS DE TRATAMENTO DE COVID-19 USANDO BARDOXOLONA METIL OU ANÁLOGOS DA MESMA. A presente invenção refere-se a métodos para tratar pacientes infectados com um coronavírus. Em particular, são fornecidos métodos para tratar ou prevenir COVID-19, ou sintomas ou complicações dos mesmos, em pacientes em necessidade dos mesmos usando bardoxolona metil ou análogos do mesmo, e/ou prevenir o aparecimento da CO-VID-19 em pacientes infectados com SARS-CoV-2.
BR112022022599A 2020-05-09 2021-05-07 Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma BR112022022599A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063022479P 2020-05-09 2020-05-09
US202063053056P 2020-07-17 2020-07-17
PCT/US2021/031282 WO2021231208A1 (en) 2020-05-09 2021-05-07 Methods of treating covid-19 using bardoxolone methyl or analogs thereof

Publications (1)

Publication Number Publication Date
BR112022022599A2 true BR112022022599A2 (pt) 2023-03-21

Family

ID=76197607

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022022599A BR112022022599A2 (pt) 2020-05-09 2021-05-07 Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma

Country Status (11)

Country Link
US (1) US20230255982A1 (pt)
EP (1) EP4146226A1 (pt)
JP (1) JP2023526567A (pt)
KR (1) KR20230022164A (pt)
CN (1) CN115803059A (pt)
AU (1) AU2021273460A1 (pt)
BR (1) BR112022022599A2 (pt)
CA (1) CA3177913A1 (pt)
IL (1) IL298008A (pt)
MX (1) MX2022014034A (pt)
WO (1) WO2021231208A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016003454B1 (pt) * 2013-08-23 2023-02-14 Reata Pharmaceuticals, Inc. Uso de composto de metil bardoxolona
WO2023115220A1 (en) * 2021-12-23 2023-06-29 Institut National De La Recherche Scientifique Drug combinations for inhibiting coronavirus replication
WO2023170187A1 (en) * 2022-03-09 2023-09-14 Technische Universität München INHIBITION OF INTRACELLULAR PATHOGEN UPTAKE BY INHIBITORS OF THE IKK-α/NIK COMPLEX
CN116509874A (zh) * 2023-02-01 2023-08-01 潍坊医学院附属医院 甲基巴多索隆在制备改善病毒性心肌炎或病毒性心肌损伤的药物中的用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
AU658374B2 (en) 1990-09-14 1995-04-13 Biosite Diagnostics Incorporated Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
WO1992018868A1 (en) 1991-04-10 1992-10-29 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
DE69231382T2 (de) 1991-04-12 2001-01-25 Biosite Diagnostics Inc Neue konjugate und testverfahren für die gleichzeitige bestimmung von multiplen liganden
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
GB9212302D0 (en) 1992-06-10 1992-07-22 Applied Research Systems Method for improving measurement precision in evanescent wave optical biosensor assays
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6025395A (en) 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
WO2003059339A1 (en) 2002-01-15 2003-07-24 Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
WO2008064133A1 (en) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
US20080280377A1 (en) 2007-05-08 2008-11-13 Abbott Laboratories Human b-type natriuretic peptide assay having reduced cross-reactivity with other peptide forms
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
KR100905466B1 (ko) 2007-10-08 2009-07-02 한국과학기술원 차세대 셀룰라 통신시스템에서의 중계 통신방법
WO2009089545A1 (en) 2008-01-11 2009-07-16 Reata Pharmaceuticals, Inc. Synthetic triterpenoids and methods of use in the treatment of disease
CN102164941B (zh) 2008-04-18 2015-05-27 里亚塔医药公司 抗氧化剂炎症调节剂:具有饱和c环的齐墩果酸衍生物
MX2010011435A (es) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
CA2721838C (en) 2008-04-18 2017-05-23 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
WO2009146216A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals. Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
BRPI0911422B8 (pt) 2008-04-18 2021-05-25 Reata Pharmaceuticals Inc compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos
PL3254675T3 (pl) 2009-02-13 2019-09-30 Reata Pharmaceuticals, Inc. Kompozycje doustne o opóźnionym uwalnianiu, zawierające amorficzny cddo-me
CN102887936A (zh) 2012-10-24 2013-01-23 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯晶型
CN102875634B (zh) 2012-10-24 2014-08-20 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯的几种晶型
BR112016003454B1 (pt) * 2013-08-23 2023-02-14 Reata Pharmaceuticals, Inc. Uso de composto de metil bardoxolona
KR102486434B1 (ko) * 2016-11-08 2023-01-09 리아타 파마슈티컬즈 홀딩스, 엘엘씨 바독솔론 메틸 또는 이의 유사체를 사용하는 알포트 증후군의 치료 방법
US11427533B2 (en) 2017-07-13 2022-08-30 Pliva Hrvatska D.O.O. Crystalline polymorphs of bardoxolone methyl

Also Published As

Publication number Publication date
EP4146226A1 (en) 2023-03-15
CN115803059A (zh) 2023-03-14
AU2021273460A1 (en) 2022-12-08
JP2023526567A (ja) 2023-06-21
CA3177913A1 (en) 2021-11-18
MX2022014034A (es) 2023-01-11
IL298008A (en) 2023-01-01
US20230255982A1 (en) 2023-08-17
KR20230022164A (ko) 2023-02-14
WO2021231208A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
BR112022022599A2 (pt) Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma
BR112021024310A2 (pt) Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus
BR112023020600A2 (pt) Método para tratar ou prevenir uma infecção, e, uso de um composto
BR112022016413A2 (pt) Método para o tratamento ou prevenção do coronavírus causado pelo vírus coronavírus da síndrome respiratória aguda grave 2, composto, e, uso de um composto
BR112022019557A2 (pt) Inibidores de replicação de norovírus e coronavírus
BR112015001419A2 (pt) composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112023002951A2 (pt) Compostos de fosfolipídio e usos destes
BR112016013961A2 (pt) angiotensina ii sozinha ou em combinação para o tratamento da hipotensão
BR112013007423A2 (pt) terapia combinada no que diz respeito ao tratamento da infecção por hcv
CL2021001976A1 (es) Tratamiento de lesiones cutáneas y prurito en pacientes con prurigo nodular
BR112022018235A2 (pt) Método de tratamento, método para tratar síndrome do desconforto respiratório agudo, método para inibir uma resposta de citocina em um paciente, método para tratar lesão renal aguda e método para tratar trombose
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
BR112021022602A2 (pt) Métodos para tratamento de urticária espontânea crônica com o uso de um inibidor de tirosina quinase de bruton
BR112022018396A2 (pt) Método de tratamento ou prevenção para insuficiência cardíaca crônica
BR112022019198A2 (pt) Composição farmacêutica para a prevenção ou tratamento de infecções por vírus de ácido ribonucleico epidêmico, e, uso de uma quantidade terapeuticamente eficaz de pironaridina ou um sal farmaceuticamente aceitável da mesma e artemisinina ou um derivado da mesma
BR112015023000A2 (pt) tratamento tópico e sistêmico combinado de tecidos desordenados
BR112023001547A2 (pt) Composição farmacêutica compreendendo liraglutida, ou gefitinib ou um de seus sais ou solvatos, e uso da mesma
BR112022019554A2 (pt) Método e composição farmacêutica para tratar uma infecção viral por ácido ribonucleico, e, uso de um composto
BR112022002692A2 (pt) Agentes antimaláricos
BR112022023637A2 (pt) Composição, e, método para prevenir ou tratar uma infecção viral
BR112022022427A2 (pt) Tratamento de infecção, doença ou distúrbio viral com o uso de um agonista de s1r seletivo
MX2016011002A (es) Tratamiento de angioedema hereditario con inhibidor c1.
WO2022186926A3 (en) Methods for inhibiting coronaviruses using sulforaphane